Beta Bionics, Inc. (BBNX) FinancialsBBNXBeta Bionics, Inc.

Beta Bionics, Inc. (BBNX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DME channel - iLet, accounting for 39.5% of total sales, equivalent to $12.65M. Other significant revenue streams include PBP channel - Single-use products and DME channel - Single-use products. Understanding this composition is critical for investors evaluating how BBNX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Beta Bionics, Inc. maintains a gross margin of 59.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -79.90%, while the net margin is -73.10%. These profitability ratios, combined with a Return on Equity (ROE) of -26.16%, provide a clear picture of how effectively BBNX converts its operational activities into shareholder value.

In the context of the broader market, BBNX competes directly with industry leaders such as CBLL and CSTL. With a market capitalization of $862.00M, it holds a significant position in the sector. When comparing efficiency, BBNX's gross margin of 59.04% stands against CBLL's 92.32% and CSTL's 74.94%. Such benchmarking helps identify whether Beta Bionics, Inc. is trading at a premium or discount relative to its financial performance.

Beta Bionics has shown a gross margin of 59.04% in Q2 2026, which is a positive sign of profitability potential. However, the company has been experiencing net losses, with a net income of -23,403,000 USD in Q2 2026.